期刊文献+

脱氧野尻霉素抑制乙型肝炎病毒复制的体外实验研究 被引量:12

The inhibitory effects of deoxynojirimycin on hepatitis B virus replication in vitro
下载PDF
导出
摘要 目的探讨脱氧野尻霉素(Deoxynojirimycin,DNJ)及其衍生物忖丁基-脱氧野尻霉素(N-butyl—De—oxynojirimycin,N—butyl—DNJ)的体外抗乙型肝炎病毒(HBV)作用。方法以HepG22.2.15细胞为模型,与药物共培养观察9d,于第3、6、9d收集培养上清行乙型肝炎表面抗原及e抗原(HBsAg及HBeAg)、HBV DNA定量检测。结果培养第9d,1000μg/mL DNJ、100μg/mL N-butyl-DNJ具有较明显抑制病毒复制的作用,与对照组比较,差异均具显著性(均P=0.001)。结论DNJ及其衍生物在实验浓度下无明显和直接的细胞毒性作用,分别在1000μg/mL、100μg/mL具有较明显的抑制HBV复制的作用。 Objective To evaluate the inhibitory activities of deoxynojirimycin (DNJ) and its derivate N-butyl-deoxynojirimycin (N-butyl DNJ) against hepatitis B virus(HBV) in vitro. Methods HepG2 2. 2. 15 cell were treated with DNJ. At 3rd, 6th and 9th day after treatment, the supernatant was collected for HBsAg, HBeAg and HBV DNA quantitative assay. Results At 9th day of incubation, 1 000 μg/mL DNJ and 100 μg/mL N-butyl-DNJ had obvious inhibitory effect on the replication of virus, there were significant differences compared with control group (both P = 0. 001 ). Conclusion DNJ and its derivate have no obvious and direct cytotoxicity effect at the experimental concentration, 1 000 μg/mL DNJ and 100 μg/mL N-butyl DNJ can inhibit the replication of HBV in HepG2 2. 2. 15 cell.
出处 《中国感染控制杂志》 CAS 2009年第1期3-6,17,共5页 Chinese Journal of Infection Control
关键词 脱氧野尻霉素 N-丁基-脱氧野尻霉素 HEPG2 2.2.15细胞 肝炎病毒 乙型 体外实验 deoxynojirimycin N-butyl-deoxynojirimycin HepG2 2. 2. 15 cells hepatitis B virus in vitro test
  • 相关文献

参考文献10

  • 1Shepard C W, Simard E P, Finelli L, et al. Hepatitis B virus infection: epidemiology and vaccination[J]. Epidemiol Rev, 2006, 28(1) :112- 125.
  • 2Feld J J, Ghany M G. Evolution of therapy for chronic hepati- tis B.. progressing from the simple to the complex[J]. Ann Intern Med,2007,147(11):806 - 808.
  • 3Asano N. Glycosidase inhibitors: update and perspectives on practical use[J]. Glycobiology, 2003, 13(10) :93R- 104R.
  • 4Liu M C, Yu M, Zhang N L, etal. Dynamic analysis of hepatitis B virus DNA and its antigens in 2. 2. 15 cells[J]. J Viral Hepat, 2004, 11(2):124- 129.
  • 5Guan R. Treatment of chronic hepatitis B infection using interferon[J]. Med J Malaysia,2005,60(Suppl B): 28 - 33.
  • 6Fenouillet E, Papandreou M J, Ian M, et al. Recombinant HIV envelope expressed in an α-glucosidase 1-deficient CHO cell line and its parental cell line in the presence of 1-deoxynojirimycin is functional[J]. Virology, 1997, 231 (1) : 89 - 95.
  • 7Taylor D L, Sunkara P S, Liu P S. 6-O-butanoylcastanospermine (MDL 28,574) inhibits glycoprotein processing and the growth of HIVs[J]. AIDS, 1991, 5(6) :693 - 698.
  • 8Tan A, van den Brock L, van Boeckel S, etal. Chemical modification of the glucosidase inhibitor 1-deoxynojirimyein structure activity relation ship[J]. J Bio Chem, 1998, 266(22): 14504- 15410.
  • 9Mehta A, Lu X, Block T M, et al. Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion[J]. Proc Natl Acad Sci U S A, 1997, 94(5):1822- 1827.
  • 10Lu X, Mehta A, Dwek R, etal. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion[J]. Virology, 1995, 213 (2):660-665.

同被引文献241

引证文献12

二级引证文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部